11β-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation

Journal of Steroid Biochemistry and Molecular Biology

Volumn 119, Issue 1-2, 2010, Pages 56-72

  Staab, Claudia A ^a   Maser, Edmund ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

11 HSD1; Glucocorticoid response; Insulin resistance; Metabolic syndrome; Obesity; Syndrome X

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; GAMMA INTERFERON; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; GROWTH HORMONE RELEASING FACTOR; HYDROCORTISONE; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; LIVER X RECEPTOR AGONIST; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MYC PROTEIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; NOTCH4 RECEPTOR; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; SOMATOMEDIN C; STEROID RECEPTOR COACTIVATOR 3; THROMBOMODULIN; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; TYROSINE AMINOTRANSFERASE;

ADIPOSE TISSUE; ARTICLE; CORTICOSTEROID BLOOD LEVEL; CORTICOSTEROID METABOLISM; CUSHING SYNDROME; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME REGULATION; EPIDEMIC; GENE TARGETING; IMMUNOMODULATION; INFLAMMATION; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION INITIATION; ANIMAL; BIOLOGICAL MODEL; GENETICS; HUMAN; METABOLISM; MOUSE; PHYSIOLOGY; REVIEW;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; GLUCOCORTICOIDS; HUMANS; IMMUNOMODULATION; INFLAMMATION; METABOLIC SYNDROME X; MICE; MODELS, BIOLOGICAL; OBESITY; RECEPTORS, GLUCOCORTICOID;

EID: 76749133138     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.12.013     Document Type: Article

References (228)

1. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., and Flier J.S. A transgenic model of visceral obesity and the metabolic syndrome. Science 294 5549 (2001) 2166-2170
2. Seckl J.R., Morton N.M., Chapman K.E., and Walker B.R. Glucocorticoids and 11β-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog. Horm. Res. 59 (2004) 359-393
3. Walker B.R., and Andrew R. Tissue production of cortisol by 11β-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann. N. Y. Acad. Sci. 1083 (2006) 165-184
4. Wamil M., and Seckl J.R. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov. Today 12 13-14 (2007) 504-520
5. Stimson R.H., Andersson J., Andrew R., Redhead D.N., Karpe F., Hayes P.C., Olsson T., and Walker B.R. Cortisol release from adipose tissue by 11β-hydroxysteroid dehydrogenase type 1 in humans. Diabetes 58 1 (2009) 46-53
6. London E., and Castonguay T.W. Diet and the role of 11β-hydroxysteroid dehydrogenase-1 on obesity. J. Nutr. Biochem. 20 7 (2009) 485-493
7. Morton N.M., and Seckl J.R. 11β-hydroxysteroid dehydrogenase type 1 and obesity. Front. Horm. Res. 36 (2008) 146-164
8. Chapman K.E., Coutinho A., Gray M., Gilmour J.S., Savill J.S., and Seckl J.R. Local amplification of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 and its role in the inflammatory response. Ann. N. Y. Acad. Sci. 1088 (2006) 265-273
9. Gilmour J.S., Coutinho A.E., Cailhier J.F., Man T.Y., Clay M., Thomas G., Harris H.J., Mullins J.J., Seckl J.R., Savill J.S., and Chapman K.E. Local amplification of glucocorticoids by 11 β-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes. J. Immunol. 176 12 (2006) 7605-7611
10. Chapman K.E., Coutinho A.E., Gray M., Gilmour J.S., Savill J.S., and Seckl J.R. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in the inflammatory response. Mol. Cell. Endocrinol. 301 1-2 (2009) 123-131
11. Stegk J.P., Ebert B., Martin H.J., and Maser E. Expression profiles of human 11β-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases. Mol. Cell. Endocrinol. 301 1-2 (2009) 104-108
12. Cai T.Q., Wong B., Mundt S.S., Thieringer R., Wright S.D., and Hermanowski-Vosatka A. Induction of 11β-hydroxysteroid dehydrogenase type 1 but not -2 in human aortic smooth muscle cells by inflammatory stimuli. J. Steroid Biochem. Mol. Biol. 77 2-3 (2001) 117-122
13. Cooper M.S., Bujalska I., Rabbitt E., Walker E.A., Bland R., Sheppard M.C., Hewison M., and Stewart P.M. Modulation of 11β-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J. Bone Miner. Res. 16 6 (2001) 1037-1044
14. Tomlinson J.W., Moore J., Cooper M.S., Bujalska I., Shahmanesh M., Burt C., Strain A., Hewison M., and Stewart P.M. Regulation of expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 142 5 (2001) 1982-1989
15. Thieringer R., Le Grand C.B., Carbin L., Cai T.Q., Wong B., Wright S.D., and Hermanowski-Vosatka A. 11 β-Hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J. Immunol. 167 1 (2001) 30-35
16. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112 12 (2003) 1796-1808
17. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259 5091 (1993) 87-91
18. Fried S.K., Bunkin D.A., and Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 83 3 (1998) 847-850
19. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., and Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112 12 (2003) 1821-1830
20. Newell-Price J., Bertagna X., Grossman A.B., and Nieman L.K. Cushing's syndrome. Lancet 367 9522 (2006) 1605-1617
21. Naeser P. Effects of adrenalectomy on the obese-hyperglycemic syndrome in mice (gene symbol ob). Diabetologia 9 5 (1973) 376-379
22. Burén J., Bergström S.A., Loh E., Söderström I., Olsson T., and Mattsson C. Hippocampal 11β-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression has a diurnal variability that is lost in the obese Zucker rat. Endocrinology 148 6 (2007) 2716-2722
23. Lu N.Z., and Cidlowski J.A. The origin and functions of multiple human glucocorticoid receptor isoforms. Ann. N. Y. Acad. Sci. 1024 (2004) 102-123
24. Kino T., Su Y.A., and Chrousos G.P. Human glucocorticoid receptor isoform β: recent understanding of its potential implications in physiology and pathophysiology. Cell. Mol. Life Sci. 66 21 (2009) 3435-3448
25. Oakley R.H., Sar M., and Cidlowski J.A. The human glucocorticoid receptor β isoform. Expression, biochemical properties, and putative function. J. Biol. Chem. 271 16 (1996) 9550-9559
26. Gougat C., Jaffuel D., Gagliardo R., Henriquet C., Bousquet J., Demoly P., and Mathieu M. Overexpression of the human glucocorticoid receptor α and β isoforms inhibits AP-1 and NF-κB activities hormone independently. J. Mol. Med. 80 5 (2002) 309-318
27. Oakley R.H., Jewell C.M., Yudt M.R., Bofetiado D.M., and Cidlowski J.A. The dominant negative activity of the human glucocorticoid receptor β isoform. Specificity and mechanisms of action. J. Biol. Chem. 274 39 (1999) 27857-27866
28. de Castro M., Elliot S., Kino T., Bamberger C., Karl M., Webster E., and Chrousos G.P. The non-ligand binding β-isoform of the human glucocorticoid receptor (hGR β): tissue levels, mechanism of action, and potential physiologic role. Mol. Med. 2 5 (1996) 597-607
29. Kino T., Manoli I., Kelkar S., Wang Y., Su Y.A., and Chrousos G.P. Glucocorticoid receptor (GR) β has intrinsic, GRα-independent transcriptional activity. Biochem. Biophys. Res. Commun. 381 4 (2009) 671-675
30. Boullu-Ciocca S., Paulmyer-Lacroix O., Fina F., Ouafik L., Alessi M.C., Oliver C., and Grino M. Expression of the mRNAs coding for the glucocorticoid receptor isoforms in obesity. Obes. Res. 11 8 (2003) 925-929
31. Pratt W.B., and Dittmar K.D. Studies with purified chaperones advance the understanding of the mechanism of glucocorticoid receptor-hsp90 heterocomplex assembly. Trends Endocrinol. Metab. 9 6 (1998) 244-252
32. Sinars C.R., Cheung-Flynn J., Rimerman R.A., Scammell J.G., Smith D.F., and Clardy J. Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes. Proc. Natl. Acad. Sci. U.S.A. 100 3 (2003) 868-873
33. Watts L.M., Manchem V.P., Leedom T.A., Rivard A.L., McKay R.A., Bao D., Neroladakis T., Monia B.P., Bodenmiller D.M., Cao J.X., Zhang H.Y., Cox A.L., Jacobs S.J., Michael M.D., Sloop K.W., and Bhanot S. Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54 6 (2005) 1846-1853
34. Rosmond R., Radulovic V., and Holm G. A brief update of glucocorticoid receptor variants and obesity risk. Ann. N. Y. Acad. Sci. 1083 (2006) 153-164
35. van Rossum E.F., and Lamberts S.W. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog. Horm. Res. 59 (2004) 333-357
36. Rosmond R. The glucocorticoid receptor gene and its association to metabolic syndrome. Obes. Res. 10 10 (2002) 1078-1086
37. Wake D.J., Rask E., Livingstone D.E., Soderberg S., Olsson T., and Walker B.R. Local and systemic impact of transcriptional up-regulation of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J. Clin. Endocrinol. Metab. 88 8 (2003) 3983-3988
38. Whorwood C.B., Donovan S.J., Flanagan D., Phillips D.I., and Byrne C.D. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 51 4 (2002) 1066-1075
39. Mastorakos G., Magiakou M.A., and Chrousos G.P. Effects of the immune/inflammatory reaction on the hypothalamic-pituitary-adrenal axis. Ann. N. Y. Acad. Sci. 771 (1995) 438-448
40. Karrow N.A. Activation of the hypothalamic-pituitary-adrenal axis and autonomic nervous system during inflammation and altered programming of the neuroendocrine-immune axis during fetal and neonatal development: lessons learned from the model inflammagen, lipopolysaccharide. Brain Behav. Immun. 20 2 (2006) 144-158
41. Harbuz M.S., Chover-Gonzalez A.J., and Jessop D.S. Hypothalamo-pituitary-adrenal axis and chronic immune activation. Ann. N. Y. Acad. Sci. 992 (2003) 99-106
42. Cutolo M., Sulli A., Pizzorni C., Craviotto C., and Straub R.H. Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 992 (2003) 107-117
43. Morand E.F., and Leech M. Hypothalamic-pituitary-adrenal axis regulation of inflammation in rheumatoid arthritis. Immunol. Cell Biol. 79 4 (2001) 395-399
44. Buske-Kirschbaum A., Jobst S., and Hellhammer D.H. Altered reactivity of the hypothalamus-pituitary-adrenal axis in patients with atopic dermatitis: pathologic factor or symptom?. Ann. N. Y. Acad. Sci. 840 (1998) 747-754
45. DiBattista J.A., Martel-Pelletier J., Antakly T., Tardif G., Cloutier J.M., and Pelletier J.P. Reduced expression of glucocorticoid receptor levels in human osteoarthritic chondrocytes. Role in the suppression of metalloprotease synthesis. J. Clin. Endocrinol. Metab. 76 5 (1993) 1128-1134
46. Schlaghecke R., Kornely E., Wollenhaupt J., and Specker C. Glucocorticoid receptors in rheumatoid arthritis. Arthritis Rheum. 35 7 (1992) 740-744
47. Neeck G., Kluter A., Dotzlaw H., and Eggert M. Involvement of the glucocorticoid receptor in the pathogenesis of rheumatoid arthritis. Ann. N. Y. Acad. Sci. 966 (2002) 491-495
48. Raddatz D., Middel P., Bockemuhl M., Benohr P., Wissmann C., Schworer H., and Ramadori G. Glucocorticoid receptor expression in inflammatory bowel disease: evidence for a mucosal down-regulation in steroid-unresponsive ulcerative colitis. Aliment. Pharmacol. Ther. 19 1 (2004) 47-61
49. Rogler G., Meinel A., Lingauer A., Michl J., Zietz B., Gross V., Lang B., Andus T., Scholmerich J., and Palitzsch K.D. Glucocorticoid receptors are down-regulated in inflamed colonic mucosa but not in peripheral blood mononuclear cells from patients with inflammatory bowel disease. Eur. J. Clin. Invest. 29 4 (1999) 330-336
50. Ricketts M.L., Shoesmith K.J., Hewison M., Strain A., Eggo M.C., and Stewart P.M. Regulation of 11 β-hydroxysteroid dehydrogenase type 1 in primary cultures of rat and human hepatocytes. J. Endocrinol. 156 1 (1998) 159-168
51. Maser E., Völker B., and Friebertshäuser J. 11 β-Hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase. Biochemistry 41 7 (2002) 2459-2465
52. Blum A., and Maser E. Enzymology and molecular biology of glucocorticoid metabolism in humans. Prog. Nucleic Acid Res. Mol. Biol. 75 (2003) 173-216
53. Zhang Y.L., Zhong X., Gjoka Z., Li Y., Stochaj W., Stahl M., Kriz R., Tobin J.F., Erbe D., and Suri V. H6PDH interacts directly with 11β-HSD1: implications for determining the directionality of glucocorticoid catalysis. Arch. Biochem. Biophys. 483 1 (2009) 45-54
54. Atanasov A.G., Nashev L.G., Gelman L., Legeza B., Sack R., Portmann R., and Odermatt A. Direct protein-protein interaction of 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the endoplasmic reticulum lumen. Biochim. Biophys. Acta 1783 8 (2008) 1536-1543
55. Seckl J.R. 11 β-hydroxysteroid dehydrogenase isoforms and their implications for blood pressure regulation. Eur. J. Clin. Invest. 23 10 (1993) 589-601
56. Nomura S., Fujitaka M., Sakura N., and Ueda K. Circadian rhythms in plasma cortisone and cortisol and the cortisone/cortisol ratio. Clin. Chim. Acta 266 2 (1997) 83-91
57. Veniant M.M., Hale C., Komorowski R., Chen M.M., St Jean D.J., Fotsch C., and Wang M. Time of the day for 11β-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice. Diabetes Obes. Metab. 11 2 (2009) 109-117
58. Smith J.B., Nolan G., and Jubiz W. The relationship between unbound and total cortisol: its usefulness in detecting CBG abnormalities. Clin. Chim. Acta 108 3 (1980) 435-445
59. Gayrard V., Alvinerie M., and Toutain P.L. Interspecies variations of corticosteroid-binding globulin parameters. Domest. Anim. Endocrinol. 13 1 (1996) 35-45
60. Persson B., Kallberg Y., Bray J.E., Bruford E., Dellaporta S.L., Favia A.D., Duarte R.G., Jornvall H., Kavanagh K.L., Kedishvili N., Kisiela M., Maser E., Mindnich R., Orchard S., Penning T.M., Thornton J.M., Adamski J., and Oppermann U. The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. Chem. Biol. Interact. 178 1-3 (2009) 94-98
61. Kotelevtsev Y., Holmes M.C., Burchell A., Houston P.M., Schmoll D., Jamieson P., Best R., Brown R., Edwards C.R., Seckl J.R., and Mullins J.J. 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. U.S.A. 94 26 (1997) 14924-14929
62. Morton N.M., Holmes M.C., Fievet C., Staels B., Tailleux A., Mullins J.J., and Seckl J.R. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 276 44 (2001) 41293-41300
63. Morton N.M., Paterson J.M., Masuzaki H., Holmes M.C., Staels B., Fievet C., Walker B.R., Flier J.S., Mullins J.J., and Seckl J.R. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53 4 (2004) 931-938
64. Tomlinson J.W., and Stewart P.M. Mechanisms of disease: selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. Nat. Clin. Pract. Endocrinol. Metab. 1 2 (2005) 92-99
65. Tomlinson J.W., Sherlock M., Hughes B., Hughes S.V., Kilvington F., Bartlett W., Courtney R., Rejto P., Carley W., and Stewart P.M. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J. Clin. Endocrinol. Metab. 92 3 (2007) 857-864
66. Hale C., and Wang M. Development of 11β-HSD1 inhibitors for the treatment of type 2 diabetes. Mini Rev. Med. Chem. 8 7 (2008) 702-710
67. Hughes K.A., Webster S.P., and Walker B.R. 11-β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin. Investig. Drugs 17 4 (2008) 481-496
68. Boyle C.D., and Kowalski T.J. 11β-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents. Expert Opin. Ther. Patents 19 6 (2009) 801-825
69. Blum A., Favia A.D., and Maser E. 11β-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds. Mol. Cell. Endocrinol. 301 1-2 (2009) 132-136
70. Morgan S.A., Sherlock M., Gathercole L.L., Lavery G.G., Lenaghan C., Bujalska I.J., Laber D., Yu A., Convey G., Mayers R., Hegyi K., Sethi J.K., Stewart P.M., Smith D.M., and Tomlinson J.W. 11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 58 11 (2009) 2506-2515
71. Ku Y.H., Koo B.K., Kwak S.H., Cho Y.M., Shin H.D., Lee H.K., Kim Y., Choi J.W., Oh B., and Park K.S. Regulatory effect of common promoter polymorphisms on the expression of the 11β-hydroxysteroid dehydrogenase type 1 gene. Horm. Res. 72 1 (2009) 25-32
72. Bryndova J., Zbankova S., Kment M., and Pacha J. Colitis up-regulates local glucocorticoid activation and down-regulates inactivation in colonic tissue. Scand. J. Gastroenterol. 39 6 (2004) 549-553
73. Zbankova S., Bryndova J., Leden P., Kment M., Svec A., and Pacha J. 11β-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis. J. Gastroenterol. Hepatol. 22 7 (2007) 1019-1023
74. Ergang P., Leden P., Bryndova J., Zbankova S., Miksik I., Kment M., and Pacha J. Glucocorticoid availability in colonic inflammation of rat. Dig. Dis. Sci. 53 8 (2008) 2160-2167
75. Cooper M.S., Rabbitt E.H., Goddard P.E., Bartlett W.A., Hewison M., and Stewart P.M. Osteoblastic 11β-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J. Bone Miner. Res. 17 6 (2002) 979-986
76. Hermanowski-Vosatka A., Balkovec J.M., Cheng K., Chen H.Y., Hernandez M., Koo G.C., Le Grand C.B., Li Z., Metzger J.M., Mundt S.S., Noonan H., Nunes C.N., Olson S.H., Pikounis B., Ren N., Robertson N., Schaeffer J.M., Shah K., Springer M.S., Strack A.M., Strowski M., Wu K., Wu T., Xiao J., Zhang B.B., Wright S.D., and Thieringer R. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 202 4 (2005) 517-527
77. Escher G., Galli I., Vishwanath B.S., Frey B.M., and Frey F.J. Tumor necrosis factor α and interleukin 1β enhance the cortisone/cortisol shuttle. J. Exp. Med. 186 2 (1997) 189-198
78. Friedberg M., Zoumakis E., Hiroi N., Bader T., Chrousos G.P., and Hochberg Z. Modulation of 11 β-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. J. Clin. Endocrinol. Metab. 88 1 (2003) 385-393
79. Iwasaki Y., Takayasu S., Nishiyama M., Tsugita M., Taguchi T., Asai M., Yoshida M., Kambayashi M., and Hashimoto K. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11β-hydroxysteroid dehydrogenase type 1) gene. Mol. Cell. Endocrinol. 285 1-2 (2008) 10-18
80. Yang Z., Zhu P., Guo C., Zhu X., and Sun K. Expression of 11β-hydroxysteroid dehydrogenase type 1 in human fetal lung and regulation of its expression by interleukin-1β and cortisol. J. Clin. Endocrinol. Metab. 94 1 (2009) 306-313
81. Hardy R.S., Filer A., Cooper M.S., Parsonage G., Raza K., Hardie D.L., Rabbitt E.H., Stewart P.M., Buckley C.D., and Hewison M. Differential expression, function and response to inflammatory stimuli of 11β-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation. Arthritis Res. Ther. 8 4 (2006) R108
82. Handoko K., Yang K., Strutt B., Khalil W., and Killinger D. Insulin attenuates the stimulatory effects of tumor necrosis factor α on 11β-hydroxysteroid dehydrogenase 1 in human adipose stromal cells. J. Steroid Biochem. Mol. Biol. 72 3-4 (2000) 163-168
83. Ignatova I.D., Kostadinova R.M., Goldring C.E., Nawrocki A.R., Frey F.J., and Frey B.M. Tumor necrosis factor-α upregulates 11β-hydroxysteroid dehydrogenase type 1 expression by CCAAT/enhancer binding protein-β in HepG2 cells. Am. J. Physiol. Endocrinol. Metab. 296 2 (2009) E367-E377
84. Tsugita M., Iwasaki Y., Nishiyama M., Taguchi T., Shinahara M., Taniguchi Y., Kambayashi M., Terada Y., and Hashimoto K. Differential regulation of 11β-hydroxysteroid dehydrogenase type-1 and -2 gene transcription by proinflammatory cytokines in vascular smooth muscle cells. Life Sci. 83 11-12 (2008) 426-432
85. Kaur K., Hardy R., Ahasan M.M., Eijken M., van Leeuwen J.P., Filer A., Thomas A.M., Raza K., Buckley C.D., Stewart P.M., Rabbitt E.H., Hewison M., and Cooper M.S. Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss. Ann. Rheum. Dis. (2009) in press, doi:10.1136/ard.2009.107466
86. Webster J.C., and Cidlowski J.A. Mechanisms of glucocorticoid-receptor-mediated repression of gene expression. Trends Endocrinol. Metab. 10 10 (1999) 396-402
87. Abraham S.M., Lawrence T., Kleiman A., Warden P., Medghalchi M., Tuckermann J., Saklatvala J., and Clark A.R. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J. Exp. Med. 203 8 (2006) 1883-1889
88. Rogatsky I., Wang J.C., Derynck M.K., Nonaka D.F., Khodabakhsh D.B., Haqq C.M., Darimont B.D., Garabedian M.J., and Yamamoto K.R. Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proc. Natl. Acad. Sci. U.S.A. 100 24 (2003) 13845-13850
89. Scheinman R.I., Gualberto A., Jewell C.M., Cidlowski J.A., and Baldwin Jr. A.S. Characterization of mechanisms involved in transrepression of NF-κ B by activated glucocorticoid receptors. Mol. Cell. Biol. 15 2 (1995) 943-953
90. De Bosscher K., Vanden Berghe W., and Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24 4 (2003) 488-522
91. Newton R., and Holden N.S. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor?. Mol. Pharmacol. 72 4 (2007) 799-809
92. Clark A.R. Anti-inflammatory functions of glucocorticoid-induced genes. Mol. Cell. Endocrinol. 275 1-2 (2007) 79-97
93. Wang J.C., Derynck M.K., Nonaka D.F., Khodabakhsh D.B., Haqq C., and Yamamoto K.R. Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc. Natl. Acad. Sci. U.S.A. 101 44 (2004) 15603-15608
94. Wei Q., Hebda-Bauer E.K., Pletsch A., Luo J., Hoversten M.T., Osetek A.J., Evans S.J., Watson S.J., Seasholtz A.F., and Akil H. Overexpressing the glucocorticoid receptor in forebrain causes an aging-like neuroendocrine phenotype and mild cognitive dysfunction. J. Neurosci. 27 33 (2007) 8836-8844
95. Chen L., Finnerty C., Gustafson W.C., Bush C.R., Chi P., Guo H., Luxon B., Fields A.P., and Thompson E.A. Genomic analysis of glucocorticoid-regulated promoters in murine T-lymphoma cells. Recent Prog. Horm. Res. 58 (2003) 155-174
96. Caldenhoven E., Liden J., Wissink S., Van de Stolpe A., Raaijmakers J., Koenderman L., Okret S., Gustafsson J.A., and Van der Saag P.T. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol. Endocrinol. 9 4 (1995) 401-412
97. Calandra T., Bernhagen J., Metz C.N., Spiegel L.A., Bacher M., Donnelly T., Cerami A., and Bucala R. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377 6544 (1995) 68-71
98. Aeberli D., Leech M., and Morand E.F. Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology (Oxford) 45 8 (2006) 937-943
99. Tilg H., and Moschen A.R. Inflammatory mechanisms in the regulation of insulin resistance. Mol. Med. 14 3-4 (2008) 222-231
100. Cancello R., and Clement K. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. Br. J. Obstet. Gynaecol. 113 10 (2006) 1141-1147
101. Michailidou Z., Jensen M.D., Dumesic D.A., Chapman K.E., Seckl J.R., Walker B.R., and Morton N.M. Omental 11β-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity. Obesity (Silver Spring) 15 5 (2007) 1155-1163
102. Koska J., Stefan N., Dubois S., Trinidad C., Considine R.V., Funahashi T., Bunt J.C., Ravussin E., and Permana P.A. mRNA concentrations of MIF in subcutaneous abdominal adipose cells are associated with adipocyte size and insulin action. Int. J. Obes. 33 8 (2009) 842-850
103. Nomiyama T., Perez-Tilve D., Ogawa D., Gizard F., Zhao Y., Heywood E.B., Jones K.L., Kawamori R., Cassis L.A., Tschop M.H., and Bruemmer D. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J. Clin. Invest. 117 10 (2007) 2877-2888
104. Inouye K.E., Shi H., Howard J.K., Daly C.H., Lord G.M., Rollins B.J., and Flier J.S. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 56 9 (2007) 2242-2250
105. Tomlinson J.W., Walker E.A., Bujalska I.J., Draper N., Lavery G.G., Cooper M.S., Hewison M., and Stewart P.M. 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 25 5 (2004) 831-866
106. Moore J.S., Monson J.P., Kaltsas G., Putignano P., Wood P.J., Sheppard M.C., Besser G.M., Taylor N.F., and Stewart P.M. Modulation of 11β-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 84 11 (1999) 4172-4177
107. Hammami M.M., and Siiteri P.K. Regulation of 11 β-hydroxysteroid dehydrogenase activity in human skin fibroblasts: enzymatic modulation of glucocorticoid action. J. Clin. Endocrinol. Metab. 73 2 (1991) 326-334
108. Jamieson P.M., Chapman K.E., Edwards C.R., and Seckl J.R. 11 β-hydroxysteroid dehydrogenase is an exclusive 11 β-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 136 11 (1995) 4754-4761
109. Liu Y.J., Nakagawa Y., Nasuda K., Saegusa H., and Igarashi Y. Effect of growth hormone, insulin and dexamethasone on 11 β-hydroxysteroid dehydrogenase activity on a primary culture of rat hepatocytes. Life Sci. 59 3 (1996) 227-234
110. Voice M.W., Seckl J.R., Edwards C.R., and Chapman K.E. 11 β-hydroxysteroid dehydrogenase type 1 expression in 2S FAZA hepatoma cells is hormonally regulated: a model system for the study of hepatic glucocorticoid metabolism. Biochem. J. 317 Part 2 (1996) 621-625
111. Napolitano A., Voice M.W., Edwards C.R., Seckl J.R., and Chapman K.E. 11β-Hydroxysteroid dehydrogenase 1 in adipocytes: expression is differentiation-dependent and hormonally regulated. J. Steroid Biochem. Mol. Biol. 64 5-6 (1998) 251-260
112. Balachandran A., Guan H., Sellan M., van Uum S., and Yang K. Insulin and dexamethasone dynamically regulate adipocyte 11β-hydroxysteroid dehydrogenase type 1. Endocrinology 149 8 (2008) 4069-4079
113. Schmitz-Peiffer C., and Biden T.J. Protein kinase C function in muscle, liver, and β-cells and its therapeutic implications for type 2 diabetes. Diabetes 57 7 (2008) 1774-1783
114. Schmitz-Peiffer C. Protein kinase C and lipid-induced insulin resistance in skeletal muscle. Ann. N. Y. Acad. Sci. 967 (2002) 146-157
115. Tetsuka M., Haines L.C., Milne M., Simpson G.E., and Hillier S.G. Regulation of 11β-hydroxysteroid dehydrogenase type 1 gene expression by LH and interleukin-1β in cultured rat granulosa cells. J. Endocrinol. 163 3 (1999) 417-423
116. Ge R.S., and Hardy M.P. Protein kinase C increases 11β-hydroxysteroid dehydrogenase oxidation and inhibits reduction in rat Leydig cells. J. Androl. 23 1 (2002) 135-143
117. Srivastava R.A. Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11β-HSD1, PEPCK and DGAT2. Comparison of PPARα, PPARγ, and liver x receptor agonists. Eur. J. Pharmacol. 607 1-3 (2009) 258-263
118. Berger J., Tanen M., Elbrecht A., Hermanowski-Vosatka A., Moller D.E., Wright S.D., and Thieringer R. Peroxisome proliferator-activated receptor-γ ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity. J. Biol. Chem. 276 16 (2001) 12629-12635
119. Alfaidy N., Xiong Z.G., Myatt L., Lye S.J., MacDonald J.F., and Challis J.R. Prostaglandin F2α potentiates cortisol production by stimulating 11β-hydroxysteroid dehydrogenase 1: a novel feedback loop that may contribute to human labor. J. Clin. Endocrinol. Metab. 86 11 (2001) 5585-5592
120. Laplante M., Sell H., MacNaul K.L., Richard D., Berger J.P., and Deshaies Y. PPAR-γ activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes 52 2 (2003) 291-299
121. Stulnig T.M., Oppermann U., Steffensen K.R., Schuster G.U., and Gustafsson J.A. Liver X receptors downregulate 11β-hydroxysteroid dehydrogenase type 1 expression and activity. Diabetes 51 8 (2002) 2426-2433
122. Wake D.J., Stimson R.H., Tan G.D., Homer N.Z., Andrew R., Karpe F., and Walker B.R. Effects of peroxisome proliferator-activated receptor-α and -γ agonists on 11β-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men. J. Clin. Endocrinol. Metab. 92 5 (2007) 1848-1856
123. Nakano S., Inada Y., Masuzaki H., Tanaka T., Yasue S., Ishii T., Arai N., Ebihara K., Hosoda K., Maruyama K., Yamazaki Y., Shibata N., and Nakao K. Bezafibrate regulates the expression and enzyme activity of 11β-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab. 292 4 (2007) E1213-E1222
124. Hermanowski-Vosatka A., Gerhold D., Mundt S.S., Loving V.A., Lu M., Chen Y., Elbrecht A., Wu M., Doebber T., Kelly L., Milot D., Guo Q., Wang P.R., Ippolito M., Chao Y.S., Wright S.D., and Thieringer R. PPARα agonists reduce 11β-hydroxysteroid dehydrogenase type 1 in the liver. Biochem. Biophys. Res. Commun. 279 2 (2000) 330-336
125. Wojcicka G., Jamroz-Wisniewska A., Horoszewicz K., and Beltowski J. Liver X receptors (LXRs). Part I: Structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig. Med. Dosw. 61 (2007) 736-759
126. Zelcer N., and Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 116 3 (2006) 607-614
127. Rigamonti E., Chinetti-Gbaguidi G., and Staels B. Regulation of macrophage functions by PPAR-α, PPAR-γ, and LXRs in mice and men. Arterioscler. Thromb. Vasc. Biol. 28 6 (2008) 1050-1059
128. Hong C., and Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr. Opin. Genet. Dev. 18 5 (2008) 461-467
129. Daynes R.A., and Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2 10 (2002) 748-759
130. Balmer J.E., and Blomhoff R. Gene expression regulation by retinoic acid. J. Lipid Res. 43 11 (2002) 1773-1808
131. Sai S., Esteves C.L., Kelly V., Michailidou Z., Anderson K., Coll A.P., Nakagawa Y., Ohzeki T., Seckl J.R., and Chapman K.E. Glucocorticoid regulation of the promoter of 11β-hydroxysteroid dehydrogenase type 1 is indirect and requires CCAAT/enhancer-binding protein-β. Mol. Endocrinol. 22 9 (2008) 2049-2060
132. Yang Z., Guo C., Zhu P., Li W., Myatt L., and Sun K. Role of glucocorticoid receptor and CCAAT/enhancer-binding protein α in the feed-forward induction of 11β-hydroxysteroid dehydrogenase type 1 expression by cortisol in human amnion fibroblasts. J. Endocrinol. 195 2 (2007) 241-253
133. Gout J., Tirard J., Thevenon C., Riou J.P., Begeot M., and Naville D. CCAAT/enhancer-binding proteins (C/EBPs) regulate the basal and cAMP-induced transcription of the human 11β-hydroxysteroid dehydrogenase encoding gene in adipose cells. Biochimie 88 9 (2006) 1115-1124
134. Hebbar P.B., and Archer T.K. Chromatin-dependent cooperativity between site-specific transcription factors in vivo. J. Biol. Chem. 282 11 (2007) 8284-8291
135. Hu A., Fatma S., Cao J., Grunstein J.S., Nino G., Grumbach Y., and Grunstein M.M. Th2 cytokine-induced upregulation of 11β-hydroxysteroid dehydrogenase-1 facilitates glucocorticoid suppression of proasthmatic airway smooth muscle function. Am. J. Physiol. Lung Cell. Mol. Physiol. 296 5 (2009) L790-803
136. Aubry E.M., and Odermatt A. Retinoic acid reduces glucocorticoid sensitivity in C2C12 myotubes by decreasing 11β-hydroxysteroid dehydrogenase type 1 and glucocorticoid receptor activities. Endocrinology 150 6 (2009) 2700-2708
137. Sakuta T., Uchiyama T., and Kanayama T. Topical ER36009, a RARγ-selective retinoid, decreases abdominal white adipose tissue and elicits changes in expression of genes related to adiposity and thermogenesis. Endocrine 30 1 (2006) 113-119
138. Sun K., and Myatt L. Enhancement of glucocorticoid-induced 11β-hydroxysteroid dehydrogenase type 1 expression by proinflammatory cytokines in cultured human amnion fibroblasts. Endocrinology 144 12 (2003) 5568-5577
139. Brasier A.R., Tate J.E., Ron D., and Habener J.F. Multiple cis-acting DNA regulatory elements mediate hepatic angiotensinogen gene expression. Mol. Endocrinol. 3 6 (1989) 1022-1034
140. Yan M., Xia C., Cheng C., Shao X., Niu S., Liu H., and Shen A. The role of TNF-α and its receptors in the production of Src-suppressed C kinase substrate by rat primary type-2 astrocytes. Brain Res. 1184 (2007) 28-37
141. Boring L., Gosling J., Chensue S.W., Kunkel S.L., Farese Jr. R.V., Broxmeyer H.E., and Charo I.F. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 100 10 (1997) 2552-2561
142. Rollins B.J., Walz A., and Baggiolini M. Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood 78 4 (1991) 1112-1116
143. Sartipy P., and Loskutoff D.J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 100 12 (2003) 7265-7270
144. Christoffels V.M., Grange T., Kaestner K.H., Cole T.J., Darlington G.J., Croniger C.M., and Lamers W.H. Glucocorticoid receptor, C/EBP, HNF3, and protein kinase A coordinately activate the glucocorticoid response unit of the carbamoylphosphate synthetase I gene. Mol. Cell. Biol. 18 11 (1998) 6305-6315
145. Reichardt H.M., Umland T., Bauer A., Kretz O., and Schutz G. Mice with an increased glucocorticoid receptor gene dosage show enhanced resistance to stress and endotoxic shock. Mol. Cell. Biol. 20 23 (2000) 9009-9017
146. Malkoski S.P., and Dorin R.I. Composite glucocorticoid regulation at a functionally defined negative glucocorticoid response element of the human corticotropin-releasing hormone gene. Mol. Endocrinol. 13 10 (1999) 1629-1644
147. Mullick J., Anandatheerthavarada H.K., Amuthan G., Bhagwat S.V., Biswas G., Camasamudram V., Bhat N.K., Reddy S.E., Rao V., and Avadhani N.G. Physical interaction and functional synergy between glucocorticoid receptor and Ets2 proteins for transcription activation of the rat cytochrome P-450c27 promoter. J. Biol. Chem. 276 21 (2001) 18007-18017
148. Gerbal-Chaloin S., Daujat M., Pascussi J.M., Pichard-Garcia L., Vilarem M.J., and Maurel P. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J. Biol. Chem. 277 1 (2002) 209-217
149. Kino T., Souvatzoglou E., Charmandari E., Ichijo T., Driggers P., Mayers C., Alatsatianos A., Manoli I., Westphal H., Chrousos G.P., and Segars J.H. Rho family Guanine nucleotide exchange factor Brx couples extracellular signals to the glucocorticoid signaling system. J. Biol. Chem. 281 14 (2006) 9118-9126
150. Jiang H.Y., Wek S.A., McGrath B.C., Scheuner D., Kaufman R.J., Cavener D.R., and Wek R.C. Phosphorylation of the α subunit of eukaryotic initiation factor 2 is required for activation of NF-κB in response to diverse cellular stresses. Mol. Cell. Biol. 23 16 (2003) 5651-5663
151. Nogami H., Hiraoka Y., Matsubara M., Nonobe E., Harigaya T., Katayama M., Hemmi N., Kobayashi S., Mogi K., Aiso S., Kawamura K., and Hisano S. A composite hormone response element regulates transcription of the rat GHRH receptor gene. Endocrinology 143 4 (2002) 1318-1326
152. Chapman M.S., Askew D.J., Kuscuoglu U., and Miesfeld R.L. Transcriptional control of steroid-regulated apoptosis in murine thymoma cells. Mol. Endocrinol. 10 8 (1996) 967-978
153. Formichi P., Radi E., Battisti C., Pasqui A., Pompella G., Lazzerini P.E., Laghi-Pasini F., Leonini A., Di Stefano A., and Federico A. Psychosine-induced apoptosis and cytokine activation in immune peripheral cells of Krabbe patients. J. Cell. Physiol. 212 3 (2007) 737-743
154. Alikhani-Koupaei R., Fouladkou F., Fustier P., Cenni B., Sharma A.M., Deter H.C., Frey B.M., and Frey F.J. Identification of polymorphisms in the human 11β-hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity. FASEB J. 21 13 (2007) 3618-3628
155. Ou X.M., Storring J.M., Kushwaha N., and Albert P.R. Heterodimerization of mineralocorticoid and glucocorticoid receptors at a novel negative response element of the 5-HT1A receptor gene. J. Biol. Chem. 276 17 (2001) 14299-14307
156. Soury B., Hentzen D., Vignal M., Christeff N., and Doly J. Induction of interferon-β gene expression by dexamethasone in murine L929 cells. Mol. Endocrinol. 9 2 (1995) 199-207
157. Tronche F., Opherk C., Moriggl R., Kellendonk C., Reimann A., Schwake L., Reichardt H.M., Stangl K., Gau D., Hoeflich A., Beug H., Schmid W., and Schutz G. Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev. 18 5 (2004) 492-497
158. Goswami R., Lacson R., Yang E., Sam R., and Unterman T. Functional analysis of glucocorticoid and insulin response sequences in the rat insulin-like growth factor-binding protein-1 promoter. Endocrinology 134 2 (1994) 736-743
159. Schweizer-Groyer G., Jibard N., Neau E., Fortin D., Cadepond F., Baulieu E.E., and Groyer A. The glucocorticoid response element II is functionally homologous in rat and human insulin-like growth factor-binding protein-1 promoters. J. Biol. Chem. 274 17 (1999) 11679-11686
160. Ray A., LaForge K.S., and Sehgal P.B. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol. Cell. Biol. 10 11 (1990) 5736-5746
161. Ray A., LaForge K.S., and Sehgal P.B. Repressor to activator switch by mutations in the first Zn finger of the glucocorticoid receptor: is direct DNA binding necessary?. Proc. Natl. Acad. Sci. U.S.A. 88 16 (1991) 7086-7090
162. Sallmann S., Juttler E., Prinz S., Petersen N., Knopf U., Weiser T., and Schwaninger M. Induction of interleukin-6 by depolarization of neurons. J. Neurosci. 20 23 (2000) 8637-8642
163. Lee H.C., Shibata H., Ogawa S., Maki K., and Ikuta K. Transcriptional regulation of the mouse IL-7 receptor α promoter by glucocorticoid receptor. J. Immunol. 174 12 (2005) 7800-7806
164. Garside H., Stevens A., Farrow S., Normand C., Houle B., Berry A., Maschera B., and Ray D. Glucocorticoid ligands specify different interactions with NF-κB by allosteric effects on the glucocorticoid receptor DNA binding domain. J. Biol. Chem. 279 48 (2004) 50050-50059
165. Lu N.Z., Collins J.B., Grissom S.F., and Cidlowski J.A. Selective regulation of bone cell apoptosis by translational isoforms of the glucocorticoid receptor. Mol. Cell. Biol. 27 20 (2007) 7143-7160
166. Lee J.K., and Tsai S.Y. Multiple hormone response elements can confer glucocorticoid regulation on the human insulin receptor gene. Mol. Endocrinol. 8 5 (1994) 625-634
167. Shears S.B. Diphosphoinositol polyphosphates: metabolic messengers?. Mol. Pharmacol. 76 2 (2009) 236-252
168. Turnbow M.A., Keller S.R., Rice K.M., and Garner C.W. Dexamethasone down-regulation of insulin receptor substrate-1 in 3T3-L1 adipocytes. J. Biol. Chem. 269 4 (1994) 2516-2520
169. Yang-Yen H.F., Chambard J.C., Sun Y.L., Smeal T., Schmidt T.J., Drouin J., and Karin M. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62 6 (1990) 1205-1215
170. Da Silva C.A., Heilbock C., Kassel O., and Frossard N. Transcription of stem cell factor (SCF) is potentiated by glucocorticoids and interleukin-1β through concerted regulation of a GRE-like and an NF-κB response element. FASEB J. 17 15 (2003) 2334-2336
171. Akcay T., Dincer Y., Celebi N., and Ilkova H. O(6)-methylguanine DNA methyltransferase activity in diabetic patients. Diabetes Res. Clin. Pract. 61 1 (2003) 1-6
172. 6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone. Oncogene 18 2 (1999) 525-532
173. Pelengaris S., Khan M., and Evan G.I. Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109 3 (2002) 321-334
174. Pelengaris S., and Khan M. The many faces of c-MYC. Arch. Biochem. Biophys. 416 2 (2003) 129-136
175. Ma T., Copland J.A., Brasier A.R., and Thompson E.A. A novel glucocorticoid receptor binding element within the murine c-myc promoter. Mol. Endocrinol. 14 9 (2000) 1377-1386
176. Deroo B.J., and Archer T.K. Glucocorticoid receptor activation of the I κ B α promoter within chromatin. Mol. Biol. Cell 12 11 (2001) 3365-3374
177. Valdes A.M., and Thomson G. Several loci in the HLA class III region are associated with T1D risk after adjusting for DRB1-DQB1. Diabetes Obes. Metab. 11 Suppl. 1 (2009) 46-52
178. Kochi Y., Yamada R., Kobayashi K., Takahashi A., Suzuki A., Sekine A., Mabuchi A., Akiyama F., Tsunoda T., Nakamura Y., and Yamamoto K. Analysis of single-nucleotide polymorphisms in Japanese rheumatoid arthritis patients shows additional susceptibility markers besides the classic shared epitope susceptibility sequences. Arthritis Rheum. 50 1 (2004) 63-71
179. Wu J., and Bresnick E.H. Glucocorticoid and growth factor synergism requirement for Notch4 chromatin domain activation. Mol. Cell. Biol. 27 6 (2007) 2411-2422
180. Stafford J.M., Waltner-Law M., and Granner D.K. Role of accessory factors and steroid receptor coactivator 1 in the regulation of phosphoenolpyruvate carboxykinase gene transcription by glucocorticoids. J. Biol. Chem. 276 6 (2001) 3811-3819
181. Wang L.L., Ou C.C., and Chan J.Y. Receptor-independent activation of GABAergic neurotransmission and receptor-dependent nontranscriptional activation of phosphatidylinositol 3-kinase/protein kinase Akt pathway in short-term cardiovascular actions of dexamethasone at the nucleus tractus solitarii of the rat. Mol. Pharmacol. 67 2 (2005) 489-498
182. Guo C., Yang Z., Li W., Zhu P., Myatt L., and Sun K. Paradox of glucocorticoid-induced cytosolic phospholipase A2 group IVA messenger RNA expression involves glucocorticoid receptor binding to the promoter in human amnion fibroblasts. Biol. Reprod. 78 1 (2008) 193-197
183. Radoja N., Komine M., Jho S.H., Blumenberg M., and Tomic-Canic M. Novel mechanism of steroid action in skin through glucocorticoid receptor monomers. Mol. Cell. Biol. 20 12 (2000) 4328-4339
184. Francis G.A., Fayard E., Picard F., and Auwerx J. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65 (2003) 261-311
185. Vang T., Congia M., Macis M.D., Musumeci L., Orru V., Zavattari P., Nika K., Tautz L., Tasken K., Cucca F., Mustelin T., and Bottini N. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 37 12 (2005) 1317-1319
186. Wang H.C., Zentner M.D., Deng H.T., Kim K.J., Wu R., Yang P.C., and Ann D.K. Oxidative stress disrupts glucocorticoid hormone-dependent transcription of the amiloride-sensitive epithelial sodium channel α-subunit in lung epithelial cells through ERK-dependent and thioredoxin-sensitive pathways. J. Biol. Chem. 275 12 (2000) 8600-8609
187. Sayegh R., Auerbach S.D., Li X., Loftus R.W., Husted R.F., Stokes J.B., and Thomas C.P. Glucocorticoid induction of epithelial sodium channel expression in lung and renal epithelia occurs via trans-activation of a hormone response element in the 5′-flanking region of the human epithelial sodium channel α subunit gene. J. Biol. Chem. 274 18 (1999) 12431-12437
188. Skurk T., and Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int. J. Obes. Relat. Metab. Disord. 28 11 (2004) 1357-1364
189. Bruzdzinski C.J., Johnson M.R., Goble C.A., Winograd S.S., and Gelehrter T.D. Mechanism of glucocorticoid induction of the rat plasminogen activator inhibitor-1 gene in HTC rat hepatoma cells: identification of cis-acting regulatory elements. Mol. Endocrinol. 7 9 (1993) 1169-1177
190. Zhang L., Cui R., Cheng X., and Du J. Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating IκB kinase. Cancer Res. 65 2 (2005) 457-464
191. Maiyar A.C., Phu P.T., Huang A.J., and Firestone G.L. Repression of glucocorticoid receptor transactivation and DNA binding of a glucocorticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein. Mol. Endocrinol. 11 3 (1997) 312-329
192. Kullak-Ublick G.A., Stieger B., and Meier P.J. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126 1 (2004) 322-342
193. Scatena M., Liaw L., and Giachelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler. Thromb. Vasc. Biol. 27 11 (2007) 2302-2309
194. Wang D., Yamamoto S., Hijiya N., Benveniste E.N., and Gladson C.L. Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions. Oncogene 19 50 (2000) 5801-5809
195. Srinivasan G., Patel N.T., and Thompson E.B. Heat shock protein is tightly associated with the recombinant human glucocorticoid receptor:glucocorticoid response element complex. Mol. Endocrinol. 8 2 (1994) 189-196
196. Scott D.K., Stromstedt P.E., Wang J.C., and Granner D.K. Further characterization of the glucocorticoid response unit in the phosphoenolpyruvate carboxykinase gene. The role of the glucocorticoid receptor-binding sites. Mol. Endocrinol. 12 4 (1998) 482-491
197. Pandit S., Geissler W., Harris G., and Sitlani A. Allosteric effects of dexamethasone and RU486 on glucocorticoid receptor-DNA interactions. J. Biol. Chem. 277 2 (2002) 1538-1543
198. Weiler H., and Isermann B.H. Thrombomodulin. J. Thromb. Haemost. 1 7 (2003) 1515-1524
199. Hermoso M.A., Matsuguchi T., Smoak K., and Cidlowski J.A. Glucocorticoids and tumor necrosis factor α cooperatively regulate toll-like receptor 2 gene expression. Mol. Cell. Biol. 24 11 (2004) 4743-4756
200. Powell W.S. 15-Deoxy-Δ12,14-PGJ2: endogenous PPARγ ligand or minor eicosanoid degradation product?. J. Clin. Invest. 112 6 (2003) 828-830
201. Lee H.Y., Acosta T.J., Skarzynski D.J., and Okuda K. Prostaglandin F2α stimulates 11β-Hydroxysteroid dehydrogenase 1 enzyme bioactivity and protein expression in bovine endometrial stromal cells. Biol. Reprod. 80 4 (2009) 657-664
202. Agha A., and Monson J.P. Modulation of glucocorticoid metabolism by the growth hormone - IGF-1 axis. Clin. Endocrinol. (Oxf.) 66 4 (2007) 459-465
203. Low S.C., Chapman K.E., Edwards C.R., Wells T., Robinson I.C., and Seckl J.R. Sexual dimorphism of hepatic 11 β-hydroxysteroid dehydrogenase in the rat: the role of growth hormone patterns. J. Endocrinol. 143 3 (1994) 541-548
204. Gao H.B., Ge R.S., Lakshmi V., Marandici A., and Hardy M.P. Hormonal regulation of oxidative and reductive activities of 11 β-hydroxysteroid dehydrogenase in rat Leydig cells. Endocrinology 138 1 (1997) 156-161
205. Paulsen S.K., Pedersen S.B., Jorgensen J.O., Fisker S., Christiansen J.S., Flyvbjerg A., and Richelsen B. Growth hormone (GH) substitution in GH-deficient patients inhibits 11β-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue. J. Clin. Endocrinol. Metab. 91 3 (2006) 1093-1098
206. Gelding S.V., Taylor N.F., Wood P.J., Noonan K., Weaver J.U., Wood D.F., and Monson J.P. The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11 β-hydroxysteroid dehydrogenase activity. Clin. Endocrinol. (Oxf.) 48 2 (1998) 153-162
207. Trainer P.J., Drake W.M., Perry L.A., Taylor N.F., Besser G.M., and Monson J.P. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. J. Clin. Endocrinol. Metab. 86 7 (2001) 2989-2992
208. Toogood A.A., Taylor N.F., Shalet S.M., and Monson J.P. Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients. J. Clin. Endocrinol. Metab. 85 4 (2000) 1727-1730
209. Bujalska I.J., Kumar S., and Stewart P.M. Does central obesity reflect "Cushing's disease of the omentum"?. Lancet 349 9060 (1997) 1210-1213
210. Tomlinson J.W., Sinha B., Bujalska I., Hewison M., and Stewart P.M. Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J. Clin. Endocrinol. Metab. 87 12 (2002) 5630-5635
211. Gupta S., Alfaidy N., Holloway A.C., Whittle W.L., Lye S.J., Gibb W., and Challis J.R. Effects of cortisol and oestradiol on hepatic 11β-hydroxysteroid dehydrogenase type 1 and glucocorticoid receptor proteins in late-gestation sheep fetus. J. Endocrinol. 176 2 (2003) 175-184
212. Nwe K.H., Hamid A., Morat P.B., and Khalid B.A. Differential regulation of the oxidative 11β-hydroxysteroid dehydrogenase activity in testis and liver. Steroids 65 1 (2000) 40-45
213. Jamieson P.M., Chapman K.E., and Seckl J.R. Tissue- and temporal-specific regulation of 11β-hydroxysteroid dehydrogenase type 1 by glucocorticoids in vivo. J. Steroid Biochem. Mol. Biol. 68 5-6 (1999) 245-250
214. Moisan M.P., Seckl J.R., and Edwards C.R. 11 β-hydroxysteroid dehydrogenase bioactivity and messenger RNA expression in rat forebrain: localization in hypothalamus, hippocampus, and cortex. Endocrinology 127 3 (1990) 1450-1455
215. Sun K., He P., and Yang K. Intracrine induction of 11β-hydroxysteroid dehydrogenase type 1 expression by glucocorticoid potentiates prostaglandin production in the human chorionic trophoblast. Biol. Reprod. 67 5 (2002) 1450-1455
216. Yong P.Y., Harlow C., Thong K.J., and Hillier S.G. Regulation of 11β-hydroxysteroid dehydrogenase type 1 gene expression in human ovarian surface epithelial cells by interleukin-1. Hum. Reprod. 17 9 (2002) 2300-2306
217. Evagelatou M., Peterson S.L., and Cooke B.A. Leukocytes modulate 11β-hydroxysteroid dehydrogenase (11β-HSD) activity in human granulosa-lutein cell cultures. Mol. Cell. Endocrinol. 133 2 (1997) 81-88
218. Velloso C.P. Regulation of muscle mass by growth hormone and IGF-I. Br. J. Pharmacol. 154 3 (2008) 557-568
219. Otero M., Lago R., Lago F., Casanueva F.F., Dieguez C., Gomez-Reino J.J., and Gualillo O. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 579 2 (2005) 295-301
220. Liu Y., Nakagawa Y., Wang Y., Li R., Li X., Ohzeki T., and Friedman T.C. Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice. Diabetes 52 6 (2003) 1409-1416
221. Kemp B.E., Stapleton D., Campbell D.J., Chen Z.P., Murthy S., Walter M., Gupta A., Adams J.J., Katsis F., van Denderen B., Jennings I.G., Iseli T., Michell B.J., and Witters L.A. AMP-activated protein kinase, super metabolic regulator. Biochem. Soc. Trans. 31 Part 1 (2003) 162-168
222. Towler M.C., and Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ. Res. 100 3 (2007) 328-341
223. Misra P., and Chakrabarti R. The role of AMP kinase in diabetes. Indian J. Med. Res. 125 3 (2007) 389-398
224. Manna S.K., and Gangadharan C. Decrease in RelA phosphorylation by inhibiting protein kinase A induces cell death in NF-κB-expressing and drug-resistant tumor cells. Mol. Immunol. 46 7 (2009) 1340-1350
225. Luo M., Jones S.M., Phare S.M., Coffey M.J., Peters-Golden M., and Brock T.G. Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J. Biol. Chem. 279 40 (2004) 41512-41520
226. Rammos G., Tseke P., and Ziakka S. Vitamin D, the rennin-angiotensin system, and insulin resistance. Int. Urol. Nephrol. 40 2 (2008) 419-426
227. Danescu L.G., Levy S., and Levy J. Vitamin D and diabetes mellitus. Endocrine 35 1 (2009) 11-17
228. Morris K.L., and Zemel M.B. 1,25-dihydroxyvitamin D3 modulation of adipocyte glucocorticoid function. Obes. Res. 13 4 (2005) 670-677